Access and Use of Medicines in Ukraine

Abstract

translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Innovative activities in healthcare institutions of the future: models for overcoming dilemmas

“…Many healthcare systems place a strong emphasis on creating efficient drug reimbursement processes that will lower healthcare costs and increase access to high-quality medical care [15]. Since April 1, 2017, the government of Ukraine has offered individuals with diabetes, asthma, and cardiovascular disease access to affordable medications.…”

Impact of reimbursement program “Аffordable Medicines” on consumptiom of beta-blockers in Ukraine in 2017-2020

“…It was estimated that 7.2 million patients with cardiovascular diseases benefited from the program in 2017, despite its recent implementation. (Olga, G.,Babar, Z. U. D, 2020).…”